A Cost-effectiveness Comparison of Bimatoprost Versus Latanoprost in Patients with Glaucoma or Ocular Hypertension

Survey of Ophthalmology

Volumn 49, Issue 2 SUPPL. 1, 2004, Pages

  Walt, John G ^a   Lee, Jeffrey T ^a  

^a ALLERGAN INC   (United States)

Author keywords

Bimatoprost; Cost effectiveness; Health economics; Latanopost; Pharmacoeconomics

Indexed keywords

BIMATOPROST; LATANOPROST;

ALGORITHM; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ALGORITHMS; AMIDES; ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; GLAUCOMA, OPEN-ANGLE; HEALTH CARE COSTS; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC;

EID: 1542358045     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2003.12.018     Document Type: Article

References (16)

1. The AGIS Investigators. The advanced glaucoma intervention study (AGIS) 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 130:2000;429-440.
2. Camras C.B., Alm A., Watson P., Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 103:1996;1916-1924.
3. DuBiner H., Cooke D., Dirks M. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 45:(Suppl 4):2001;S353-S360.
4. Gandolfi S., Simmons S.T., Sturm R. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 18:2001;110-121.
5. Higginbotham E.J., Schuman J.S., Goldberg I. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 120:2002;1286-1293.
6. Kass M.A., Heuer D.K., Higginbotham E.J. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 120:2002;701-713. discussion 829-30.
7. Kobelt G. Health Economics: An Introduction to Economic Evaluation. 2002;Office of Health Economics, London.
8. Leske M.C., Heijl A., Hussein M. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 121:2003;48-56.
9. Mick A.B., Gonzalez S., Dunbar M.T., McSoley J.J. A Cost analysis of the prostaglandin analogs. Optometry. 73:2002;614-619.
10. Noecker R.S., Dirks M.S., Choplin N.T. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 135:2003;55-63.
11. Parrish R.K., Palmberg P., Sheu W.P. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 135:2003;688-703.
12. Physicians Fee & Coding Guide. 2003;MAG Mutual HealthCare Consultants, Augusta, GA.
13. PriceAlert, The Official Guide to Average Wholesale Pricing. 2003;Facts & Comparisons, Indianapolis.
14. Rittenhouse B. Uses of models in economic evaluations of medicines and other health technologies. 1996;Office of Health Economics, London.
15. Serle J., Cantor L., Gross R. Best practice treatment algorithm for primary open-angle glaucoma: implications for U.S. ophthalmology practice. Manag Care Interface. 15:2002;37-48.
16. Strutton DR, Walt JG: Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma (in press)